CN101648027A - 正电子断层显像诊断放射性药物及其制备方法 - Google Patents
正电子断层显像诊断放射性药物及其制备方法 Download PDFInfo
- Publication number
- CN101648027A CN101648027A CN200910040060A CN200910040060A CN101648027A CN 101648027 A CN101648027 A CN 101648027A CN 200910040060 A CN200910040060 A CN 200910040060A CN 200910040060 A CN200910040060 A CN 200910040060A CN 101648027 A CN101648027 A CN 101648027A
- Authority
- CN
- China
- Prior art keywords
- pet
- reaction tube
- post
- positron emission
- emission tomography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002600 positron emission tomography Methods 0.000 title claims abstract description 24
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002243 precursor Substances 0.000 claims abstract description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 45
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- JTLAIKFGRHDNQM-NUTRPMROSA-N 1-bromo-2-fluoranylethane Chemical compound [18F]CCBr JTLAIKFGRHDNQM-NUTRPMROSA-N 0.000 claims description 8
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- VWFYOEMCSOFBFH-UHFFFAOYSA-N CC1=NC=CC2=CC=CC=C12.NP(=O)=O Chemical compound CC1=NC=CC2=CC=CC=C12.NP(=O)=O VWFYOEMCSOFBFH-UHFFFAOYSA-N 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 3
- 239000003446 ligand Substances 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000003335 steric effect Effects 0.000 abstract description 3
- 238000005804 alkylation reaction Methods 0.000 abstract description 2
- VHPYNVZYZFYVII-UHFFFAOYSA-N fluoroethane Chemical compound [CH2]CF VHPYNVZYZFYVII-UHFFFAOYSA-N 0.000 abstract 2
- 238000001514 detection method Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 102100031274 Translocator protein Human genes 0.000 description 5
- 101710166801 Translocator protein Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- JTLAIKFGRHDNQM-UHFFFAOYSA-N 1-bromo-2-fluoroethane Chemical compound FCCBr JTLAIKFGRHDNQM-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
试剂名称 | 用量 |
K2CO3 | 30mg |
纯水 | 1ml |
K2.2.2 | 130mg |
HPLC级乙腈 | 10ml |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100400605A CN101648027B (zh) | 2009-06-09 | 2009-06-09 | 正电子断层显像诊断放射性药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100400605A CN101648027B (zh) | 2009-06-09 | 2009-06-09 | 正电子断层显像诊断放射性药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101648027A true CN101648027A (zh) | 2010-02-17 |
CN101648027B CN101648027B (zh) | 2011-03-23 |
Family
ID=41670425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100400605A Active CN101648027B (zh) | 2009-06-09 | 2009-06-09 | 正电子断层显像诊断放射性药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101648027B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113105432A (zh) * | 2021-03-30 | 2021-07-13 | 上海交通大学医学院附属仁济医院 | 一种碳-11(11c)放射性药物及其制备方法和应用 |
CN113321616A (zh) * | 2021-06-09 | 2021-08-31 | 江苏华益科技有限公司 | 阿茨海默症β淀粉蛋白沉积显像药物前体的合成方法 |
CN113387896A (zh) * | 2021-06-17 | 2021-09-14 | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 一种4-(2-氯芳基)喹唑啉-2-酰胺衍生物及其应用 |
CN115400232A (zh) * | 2021-05-26 | 2022-11-29 | 汉中汉核医疗科技有限公司 | 一种放射性药物合成方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0523506D0 (en) * | 2005-11-18 | 2005-12-28 | Hammersmith Imanet Ltd | Novel in vivo imaging compounds |
CN101429161A (zh) * | 2008-12-05 | 2009-05-13 | 常熟理工学院 | Pet显像剂前体异喹啉甲酰胺衍生物的合成方法 |
-
2009
- 2009-06-09 CN CN2009100400605A patent/CN101648027B/zh active Active
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113105432A (zh) * | 2021-03-30 | 2021-07-13 | 上海交通大学医学院附属仁济医院 | 一种碳-11(11c)放射性药物及其制备方法和应用 |
CN113105432B (zh) * | 2021-03-30 | 2022-03-04 | 上海交通大学医学院附属仁济医院 | 一种碳-11(11c)放射性药物及其制备方法和应用 |
CN115400232A (zh) * | 2021-05-26 | 2022-11-29 | 汉中汉核医疗科技有限公司 | 一种放射性药物合成方法 |
CN113321616A (zh) * | 2021-06-09 | 2021-08-31 | 江苏华益科技有限公司 | 阿茨海默症β淀粉蛋白沉积显像药物前体的合成方法 |
CN113387896A (zh) * | 2021-06-17 | 2021-09-14 | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 一种4-(2-氯芳基)喹唑啉-2-酰胺衍生物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101648027B (zh) | 2011-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5684333B2 (ja) | 放射性ハロゲン標識有機化合物の製造方法 | |
Pascali et al. | Dose-on-demand of diverse 18F-fluorocholine derivatives through a two-step microfluidic approach | |
JP4550141B2 (ja) | 放射性フッ素標識有機化合物の製造方法 | |
CA2709558C (en) | Process for production of radioactive-fluorine-labeled organic compound | |
CN109384806B (zh) | 一种[18f]fbpa新型制备方法 | |
CN101648027B (zh) | 正电子断层显像诊断放射性药物及其制备方法 | |
Xu et al. | 18F–labeled estradiol derivative for targeting estrogen receptor-expressing breast cancer | |
Pekošak et al. | Improved synthesis and application of [11C] benzyl iodide in positron emission tomography radiotracer production | |
Kniess et al. | “Hydrous 18F-fluoroethylation”–Leaving off the azeotropic drying | |
CN103254139A (zh) | 新型18f标记4-氨基喹唑啉类衍生物及其制备方法和肿瘤pet显像应用 | |
TWI401212B (zh) | 自鎵製程廢液獲取高純度銅-64同位素之方法 | |
Goud et al. | Automated radiosynthesis and molecular docking studies of coumarin-triazole hybrid with fluorine-18: a feasibility study | |
CN113105432B (zh) | 一种碳-11(11c)放射性药物及其制备方法和应用 | |
CN109320500B (zh) | 一种18f标记的苯并咪唑类化合物及其制备方法和应用 | |
CN104945399B (zh) | 一种莫西沙星杂质c的制备方法 | |
JP6037330B2 (ja) | 11c−標識チアミン及びその誘導体、11c−標識フルスルチアミン、チアミン前駆体、並びにpet用プローブ及びそれらを用いたイメージング方法 | |
Huang et al. | F.; Automated Production of GMP-Compliant 18F-FES as na Estrogen Receptor Ligand for Breast Cancer Imaging | |
TWI504412B (zh) | f正子放射性同位素標誌之血清素運轉器造影劑的製造方法 | |
Quang et al. | Manufactrure Of Full Automatic Synthesizer To Prepare 18f-Fch Radio Pharmaceutical | |
CN103945851A (zh) | 使用二芳基碘鎓盐前体制备氟-18标记的氟马西尼的方法 | |
US10934314B1 (en) | Method for preparing organoboron derivative containing oxygen and aromatic ring as labeled precursor of dopamine positron emission tomography imaging agent | |
CN109922837A (zh) | 用于临床应用的[f-18]fddnp的多剂量合成方法 | |
Issa et al. | Synthesis and radiolabelling of ipratropium and tiotropium for use as pet ligands in the study of inhaled drug deposition | |
Wen et al. | Radiosynthesis of novel N‐18F‐labeled 18F‐FHex‐α‐l‐Glu and 18F‐FHex‐β‐Glu | |
Yasui | I. Facile preparation of ortho-fluorophenols from non-aromatic precursors and investigation of applications to fluorine-18 labeling. II. Resin-supported silyl ester precursors for kit-like radiolabeling with fluorine-18 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGDONG HUIXUAN PHARMACEUTICAL TECHNOLOGY CO., L Free format text: FORMER OWNER: WANG MINGFANG Effective date: 20150716 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150716 Address after: 510000, building 43, tower 191, Sinopec tower, No. 4323 West Sports Road, Guangzhou, Guangdong, Tianhe District, Patentee after: Guangdong Huixuan Pharmaceutical Technology Co., Ltd. Address before: 134, 510000, west gate, 1838, North Guangzhou Avenue, Baiyun District, Guangdong, Guangzhou, 301 Patentee before: Wang Mingfang |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 510000 No.1, DongXuan Road, Guangzhou Economic and Technological Development Zone, Guangzhou, Guangdong Province Patentee after: GUANGDONG HUIXUAN MEDICINE TECHNOLOGY Co.,Ltd. Address before: 510000, building 43, tower 191, Sinopec tower, No. 4323 West Sports Road, Guangzhou, Guangdong, Tianhe District, Patentee before: GUANGDONG HUIXUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Positron emission tomography in the diagnosis of radiopharmaceuticals and its preparation Effective date of registration: 20210616 Granted publication date: 20110323 Pledgee: Bank of China Limited by Share Ltd. Guangzhou Liwan branch Pledgor: GUANGDONG HUIXUAN MEDICINE TECHNOLOGY Co.,Ltd. Registration number: Y2021980004792 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |